Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. Several other ...
Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Y-Mabs Therapeutics (YMAB – Research Report). The associated price ...
Analysts at Brookline Capital Management issued their FY2024 earnings per share (EPS) estimates for shares of Y-mAbs ...
Canaccord Genuity analyst John Newman has maintained their bullish stance on YMAB stock, giving a Buy rating on December 4.Pick the best ...
Hosted on MSN7d
Brookline Capital Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Buy RecommendationFintel reports that on December 5, 2024, Brookline Capital initiated coverage of Y-mAbs Therapeutics (NasdaqGS:YMAB) with a ...
Across the recent three months, 5 analysts have shared their insights on Y-mAbs Therapeutics (NASDAQ:YMAB), expressing a variety of opinions spanning from bullish to bearish. The following table ...
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a commercial-stage biopharmaceutical company valued at $460 million, has garnered attention from analysts for its innovative approach to cancer treatment ...
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company ...
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a commercial-stage biopharmaceutical company valued at $460 million, has garnered attention from analysts for its innovative approach to cancer treatment, ...
NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback